



UvA-DARE (Digital Academic Repository)

Neuroanatomical alterations in people with high and low cannabis dependence

Lorenzetti, V.; Chye, Y.; Suo, C.; Walterfang, M.; Lubman, D.I.; Takagi, M.; Whittle, S.; Verdejo-Garcia, A.; Cousijn, J.; Pantelis, C.; Seal, M.; Fornito, A.; Yücel, M.; Solowij, N.

DOI

[10.1177/0004867419859077](https://doi.org/10.1177/0004867419859077)

Publication date

2020

Document Version

Final published version

Published in

Australian and New Zealand Journal of Psychiatry

License

Article 25fa Dutch Copyright Act

[Link to publication](#)

Citation for published version (APA):

Lorenzetti, V., Chye, Y., Suo, C., Walterfang, M., Lubman, D. I., Takagi, M., Whittle, S., Verdejo-Garcia, A., Cousijn, J., Pantelis, C., Seal, M., Fornito, A., Yücel, M., & Solowij, N. (2020). Neuroanatomical alterations in people with high and low cannabis dependence. *Australian and New Zealand Journal of Psychiatry*, 54(1), 68-75. <https://doi.org/10.1177/0004867419859077>



General rights

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: <https://uba.uva.nl/en/contact>, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

Neuroanatomical alterations in people with high and low cannabis dependence

Valentina Lorenzetti^{1,2} , Yann Chye³, Chao Suo³, Mark Walterfang^{4,5,6}, Dan I Lubman⁷ , Michael Takagi⁸, Sarah Whittle⁴, Antonio Verdejo-Garcia³, Janna Cousijn⁹, Christos Pantelis^{4,5}, Marc Seal⁸, Alex Fornito³, Murat Yücel³ and Nadia Solowij¹⁰

Australian & New Zealand Journal of Psychiatry
2020, Vol. 54(1) 68–75
DOI: 10.1177/0004867419859077

© The Royal Australian and
New Zealand College of Psychiatrists 2019
Article reuse guidelines:
sagepub.com/journals-permissions
journals.sagepub.com/home/anp



Abstract

Objectives: We aimed to investigate whether severity of cannabis dependence is associated with the neuroanatomy of key brain regions of the stress and reward brain circuits.

Methods: To examine dependence-specific regional brain alterations, we compared the volumes of regions relevant to reward and stress, between high-dependence cannabis users (CD+, $n = 25$), low-dependence cannabis users (CD-, $n = 20$) and controls ($n = 37$).

Results: Compared to CD- and/or controls, the CD+ group had lower cerebellar white matter and hippocampal volumes, and deflation of the right hippocampus head and tail.

Conclusion: These findings provide initial support for neuroadaptations involving stress and reward circuits that are specific to high-dependence cannabis users.

Keywords

Cannabis, dependence, neuroanatomy, magnetic resonance imaging, hippocampus, caudate, pituitary gland, cerebellum

Introduction

Cannabis dependence (CD) affects over 13 million individuals worldwide and has the second highest global treatment burden for illicit substances (United Nations Office on Drugs and Crime [UNODC], 2016). Over 28% of admissions to treatment services for drug use problems are cannabis-specific (UNODC, 2016). Individuals with CD represent the most vulnerable of cannabis users and experience impaired mental health and well-being relative to recreational cannabis users and non-using controls (Pol et al., 2013). A key feature of dependence is compulsive drug use driven by negative reinforcement (i.e. negative emotions or distress when one cannot access drugs), despite the physical or psychological problems associated with maladaptive use patterns (e.g. neglect of obligations and impaired quality of life; American Psychiatric Association [APA], 2013). Drug dependence has been linked to neuroadaptations in neural circuits involved in reward, stress and motivation (Everitt and Robbins, 2016; Koob, 2009; Volkow et al., 2013). Neuroanatomical alterations of structures within these circuits (e.g. hippocampus, amygdala, striatum, and

¹School of Behavioural and Health Sciences, Faculty of Health Sciences, Australian Catholic University, Fitzroy, VIC, Australia

²Department of Psychological Sciences, Institute of Psychology Health and Society, University of Liverpool, Liverpool, UK

³Brain Mind and Society Research Hub, Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Melbourne, Australia

⁴Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne, Melbourne, VIC, Australia

⁵Florey Institute of Neuroscience and Mental Health, The University of Melbourne

⁶Neuropsychiatry Unit, Royal Melbourne Hospital, Australia

⁷Turning Point, Eastern Health and Eastern Health Clinical School, Monash University, Melbourne, VIC Australia

⁸Murdoch Children's Research Institute, Parkville, VIC, Australia

⁹Department of Developmental Psychology, University of Amsterdam, Amsterdam, The Netherlands

¹⁰School of Psychology and Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, NSW, Australia

Corresponding author:

Valentina Lorenzetti, School of Behavioural and Health Sciences, Faculty of Health Sciences, Australian Catholic University, 115 Victoria Parade, Fitzroy, VIC 3065, Australia.

Email: valentina.lorenzetti@gmail.com

cerebellum) have been found in neuroimaging studies of regular cannabis users (Lorenzetti et al., 2016). However, neuroimaging studies of regular cannabis users have not consistently differentiated cannabis users with and without dependence/problematic use. Rather, they have compared regular cannabis users poorly characterised for levels of dependence to non-cannabis using controls. It is unclear whether cannabis users with and without CD show dissociable neural alterations as postulated by neuroscientific models of addiction (Everitt and Robbins, 2016; Koob, 2009; Volkow et al., 2013).

To address this knowledge gap, we compared neuro-anatomical features between cannabis users with high-dependence (CD+), low-dependence (CD-) and controls. Specifically, we examined whether the volumes of brain regions that neuroscientific models of addiction implicate in reward, stress regulation, learning and memory, and emotion regulation differ between these groups. Regions included the amygdala, hippocampus, pituitary, nucleus accumbens (NAc), caudate, putamen, pallidum and the cerebellum (total, grey matter [GM] and white matter [WM]). We hypothesised that CD+ relative to CD- and controls would show reduced medial temporal and cerebellar volumes, and larger volumes of reward and stress regions (i.e. pituitary and striatal regions). We followed up hippocampal volume results with shape analyses to identify alterations specific to hippocampal subregions.

Methods

We recruited 45 regular cannabis users, which included 25 CD+ and 20 CD- defined using the cut-off of the *Severity of Dependence Scale* (SDS) ≥ 4 (Gossop et al., 1995). We also recruited 37 non-user controls. All participants had no recent or past medical or psychiatric conditions and had limited illicit substance use (apart from cannabis use in users). All assessments were conducted by trained researchers and student researchers. *Global Assessment of Functioning* scores were estimated as part of the Structured Clinical Interview for DSM-IV-TR (SCID) assessment (Bodlund et al., 1994). Intelligence quotient was assessed with the *Wechsler Abbreviated Scale of Intelligence* (Wechsler, 1999). Depressive, and positive and negative psychotic symptoms were measured using the *Community Assessment of Psychic Experiences* (CAPE; Konings et al., 2006), and trait anxiety was assessed with the *Spielberger State-Trait Anxiety Inventory* (STAI; Spielberger, 2010). Past month alcohol dosage in standard drinks was estimated using the *Timeline Followback* procedure (Sobell and Sobell, 1992). Lifetime cannabis use was assessed with a detailed semi-structured interview used in previous works (Lorenzetti et al., 2015; Solowij et al., 2002, 2011a, 2011b; Takagi et al., 2011a, 2011b; Yücel et al., 2008). This provided information on cannabis use frequency (days/month), duration of regular cannabis use and lifetime cannabis

dosage (daily dosage \times smoking days/month \times months of regular use). Lifetime cannabis dosage was standardised to cones via the following method – <https://ncpic.org.au/static/pdfs/assessment-tools/timeline-followback.pdf>. CD severity scores were obtained using the SDS (Budney et al., 1999).

MRI data acquisition

T1-weighted structural magnetic resonance (MR) images were acquired with a 3T Siemens TIM Trio scanner with a 32-channel head coil. Images were acquired sagittally with a high-resolution imaging three-dimensional (3D) magnetization-prepared rapid acquisition with gradient echo (MPRAGE) sequence (time to repetition [TR] = 1900 ms, time to echo [TE] = 2.15 ms, field of view [FOV] = 256 mm) and were resized to 1 mm³ isotropic voxels.

MRI data processing

Each amygdala, hippocampus and pituitary were manually delineated in the coronal plane where these regions are best visualised, using validated protocols. The same investigator (V.L.) performed all tracings while blind to group status and using Analyze 11.0 (AnalyzeDirect, Overland Park, KS). Volumetric estimates were obtained by summing all voxels within traced regions of interest on consecutive coronal slices. For each region, inter- and intra-rater reliabilities for manual tracings were computed using intraclass correlation coefficients (ICCs), absolute agreement based on 10 randomly selected images.

We defined the boundaries of the amygdala using the protocol developed by Velakoulis et al. (1999, 2006), with slight modifications based on Watson et al.'s (1992) protocol for defining the boundary between the amygdala and the hippocampus. In addition, we considered the *anterior* boundary of the amygdala as either the slice posterior to where the optic chiasm joins or where the lateral sulcus closes to form the entorhinal sulcus, whichever was more posterior. ICCs for right and left amygdala volumes were 0.96 and 0.91, respectively, for intra-rater reliability, and 0.95 and 0.88, respectively, for inter-rater reliability, as compared with an experienced amygdala tracer (SLW).

The hippocampus was traced following reliable and validated protocols (Convit et al., 1999; Cook et al., 1992; Velakoulis et al., 2006). The hippocampal boundaries were as follows: *posterior*, the slice with the greatest length of continuous fornix; *medial*, the open end of the hippocampal fissure posteriorly, the uncus fissure in the hippocampal body and the medial aspect of the ambient gyrus anteriorly; *lateral*, the temporal horn of the lateral ventricle; *inferior*, the WM inferior to the hippocampus; *superior*, the superior border of the hippocampus; and *anterior*, the alveus was used to differentiate the hippocampal head from the amygdala. The anterior border was the most difficult to identify consistently

and was aided by moving between slices before and after the index slice. ICC for right and left hippocampal volumes were 0.95 and 0.93, respectively, for intra-rater reliability, and 0.92 and 0.84, respectively, for inter-rater reliability, compared to an experienced hippocampus tracer (SLW).

The pituitary gland was traced using a modified version (Pariante et al., 2004) of a reliable and validated method (MacMaster et al., 2006; MacMaster and Kusumakar, 2004; Sassi et al., 2001). We excluded the infundibular stalk from the tracing, but included the hyper-intense region in the posterior pituitary, which is thought to represent high levels of vasopressin concentrations (Garner et al., 2005; Pariante et al., 2004; Sassi et al., 2001). The borders of the pituitary were clearly defined *superiorly* by the diaphragma sellae, *inferiorly* by the sphenoid sinus and *bilaterally* by the cavernous sinuses (Garner et al., 2005; Pariante et al., 2004). ICCs for intra- and inter-rater reliabilities (compared to an experienced tracer, SLW) were 0.94 and 0.98, respectively.

Finally, the caudate, NAc, pallidum, putamen, cerebellar cortex and cerebellar GM and WM were automatically extracted with FreeSurfer v.4.1.0 (<http://surfer.nmr.mgh.harvard.edu/>). These regions were visually inspected in the coronal plane to confirm the validity of the allocated boundaries, and for outliers using scatter plots of their volumes, following standardised and publicly available protocols (<http://enigma.ini.usc.edu/protocols/imaging-protocols/>).

Statistical analyses

Chi-square tests were run to compare groups by sex distribution. A series of analyses of variance (ANOVAs) were run to compare groups on demographics (i.e. age), global function, psychopathology symptom scores (e.g. CAPE depressive, positive and negative psychotic symptoms), STAI-Trait anxiety and substance use (e.g. alcohol standard drinks/month, cannabis smoking days/month, cumulative lifetime dosage in cones, duration of regular use and SDS severity of CD).

Separate analyses of covariance (ANCOVAs) were run for each brain region to assess for the main effect of CD, with hemisphere as repeated-measure (except pituitary), and group (i.e. controls, CD-, and CD+) and sex as between-subject factors. Of the possible covariates – age, intracranial volume (ICV), global functioning, level of alcohol use, and depressive and anxiety symptom scores, we kept those that were significant predictors in the models. We explored the role of dosage and dependence on brain volumes separately in CD+ and CD- using hierarchical linear regressions with ICV and sex included as block one predictors, and cumulative lifetime dosage in cones and SDS score as block two predictors.

An exploratory analysis of hippocampal shape was run, to compare subregional differences between groups. This analysis was motivated by the considerable evidence of hippocampal volume alteration (Lorenzetti et al., 2019) and

emerging evidence of potential shape alteration associated with cannabis use (Chye et al., 2019; Solowij et al., 2013). We sought to verify previous hippocampal shape findings and extend upon these by examining CD-related associations. The manually traced hippocampi were transformed into a mesh output using the SPHARM shape analysis pipeline. Group differences were assessed, controlling for sex and ICV, using SPHARM-PDM (<http://www.nitrc.org/projects/spharm-pdm>). Use of the manually traced (i.e. the gold standard for brain analysis) hippocampal region affords us more confidence in the sensitivity of the delineated boundary shape.

Results

Sample characteristics and brain volumes are shown in Tables 1 and 2, respectively. All groups were matched by age, sex and monthly standard drinks. The CD- group had lower global functioning than controls. The CD+ group had lower IQ than controls, and lower global functioning and higher trait anxiety than the CD- and control groups. The CD+ and CD- groups were matched on lifetime cannabis dosage in cones and years of regular cannabis use, but the CD+ group had higher smoking days/month and higher CD scores.

There was a significant main effect of group on the volumes of cerebellar WM ($p=0.014$, $\eta_p^2=0.107$), hippocampus ($p<0.001$, $\eta_p^2=0.23$) and the caudate ($p=0.049$, $\eta_p^2=0.077$), although the effect for the caudate did not survive false discovery rate (FDR) correction (critical value=0.018). Cerebellar WM volumes were lower in CD+ than controls ($p=0.004$) and were predicted by severity of CD (SDS scores, $p=0.019$, right hemisphere); however, this latter effect did not survive FDR correction. Hippocampal volumes were smaller in CD+ compared to CD- ($p=0.020$) and controls ($p<0.001$). Caudate volumes were larger in CD+ compared to CD- ($p=0.019$), although this effect did not survive FDR correction. No other significant effects were found.

Exploratory shape analysis (i.e. group comparison between healthy controls [HC], CD+ and CD-, controlling for xyz) was conducted on the hippocampus, given the strength of hippocampal volumetric findings. The right hippocampal head and tail shape was altered in CD+ compared to controls (i.e. inward shape deformation; Figure 1). There were no other significant effects.

Discussion

In line with previous findings in regular cannabis users (Lorenzetti et al., 2016), we found that cannabis use was related to the structural integrity of the cerebellum, hippocampus and caudate. However, we found that alterations in some structures were specific to those with more severe dependence. Specifically, we found that CD+ had lower cerebellar WM volumes, and deflation within the hippocampus head and tail, relative to controls. CD+ had

Table 1. Sample characteristics of non-cannabis using controls, low-dependence cannabis users (CD-) and high-dependence cannabis users (CD+), presented as mean (SD).

	Controls	CD-	CD+	p-value	post hoc
Total N (females)	37 (19)	20 (10)	25 (13)	0.99	–
Age (years)	29.95 (11.29)	36.25 (11.75)	31.28 (10.44)	0.13	–
WASI-IQ	112.32 (12.72)	106.35 (11.43)	100.52 (11.67)	0.001**	Controls > CD+, $p < 0.001$ ***
GAF	86.30 (4.33)	77.85 (9.64)	72.44 (10.03)	< 0.001***	Controls > CD-, $p < 0.001$ *** Controls > CD+, $p < 0.001$ *** CD- > CD+, $p = 0.024$ *
CAPE depressive symptoms	12.11 (2.87)	13.05 (2.44)	15.40 (3.86)	0.001**	Controls < CD+, $p < 0.001$ *** CD- < CD+, $p = 0.014$ *
CAPE positive symptoms	24.20 (2.61)	27.45 (6.79)	26.96 (5.12)	0.024*	Controls < CD-, $p < 0.017$ * Controls > CD+, $p < 0.031$ *
CAPE negative symptoms	21.97 (5.51)	21.75 (3.93)	27.64 (6.81)	< .001***	Controls < CD+, $p < 0.001$ *** CD- < CD+, $p = 0.001$ **
STAI-T	33.73 (7.59)	31.20 (12.13)	44.24 (13.67)	< 0.001***	Controls < CD+, $p < 0.001$ *** CD- < CD+, $p < 0.001$ ***
Alcohol (StDr/mth)	19.79 (26.72)	21.03 (27.32)	26.11 (29.12)	0.67	–
Cannabis use					
Frequency (days/month)	–	21.15 (10.50)	26.64 (5.35)	0.03*	–
Lifetime dosage (cones ^a)	–	68,251 (60,998)	83,377 (98,002)	0.55	–
Duration of use (years)	–	17.35 (10.36)	14.64 (9.59)	0.37	–
Dependence (SDS)	–	1.45 (0.89)	7.64 (3.25)	< 0.001***	–

WASI: Wechsler Abbreviated Scale of Intelligence; GAF: Global Assessment of Functioning scale; CAPE: Community Assessment of Psychic Experiences; STAI-T: State-Trait Anxiety Inventory – Trait anxiety; StDr/mth: number of standard drinks per month; SDS: Severity of Dependence Scale.

^aCones: unit of measurement of cannabis dosage as per timeline followback (<https://ncpic.org.au/static/pdfs/assessment-tools/timeline-followback.pdf>).

* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.

lower hippocampal volumes relative to CD- and controls. In addition, CD+ had larger caudate volumes relative to CD- (Chye et al., 2017). No significant group differences emerged for the volumes of the amygdala, NAc, pallidum, putamen, pituitary and cerebellar cortex.

Volumetric alterations in individuals with high levels of CD may be specific to regions involved in substance dependence. The hippocampus and the cerebellum have been involved in the formation of drug-related and emotional memories involved in craving and drug-taking (Everitt and Robbins, 2016; Koob, 2009; Volkow et al., 2013). The cerebellum has been implicated in aberrant reward processing and motivation in drug dependence (Casajuana et al., 2016) and the hippocampus in altered stress, reward, and learning and memory in cannabis users. Volumetric reductions of the hippocampus are consistent with the results of a recent meta-analysis comparing brain volumes between cannabis users and controls (Lorenzetti et al., 2019). This meta-analysis did not segregate dependent and non-dependent cannabis users as this information

was lacking in most studies (Lorenzetti et al., 2019). The meta-analysed samples of regular cannabis users may have comprised both dependent and non-dependent cannabis users (Budney et al., 2019), and it is possible that dependent cannabis users may have driven the observed hippocampal volume reduction.

Alteration of cerebellar neuroanatomy has been reported in several structural neuroimaging studies of regular cannabis users (Blithikioti et al., 2019; Solowij et al., 2011b). It is unclear whether specific cerebellar regions are vulnerable to cannabis use and dependence. The literature to date has examined heterogeneous cerebellar regions (e.g. total volume, vermis, grey and/or WM, and distinct lobules) and has relied on distinct methods to parcellate the cerebellum in different portions. Also, knowledge of the role of the cerebellum in addiction and other psychopathology is limited as its inferior portion is commonly cut off or ‘sacrificed’ in MRI acquisition sequences, to include higher order cortical regions.

CD+ had larger caudate volumes than CD-. The caudate is part of the corticostriatal circuit implicated in addiction

Table 2. Subcortical volumes in non-cannabis using controls, low-dependence cannabis users (CD-) and high-dependence cannabis users (CD+), presented as mean (SD).

		Controls N=37	CD- N=20	CD+ N=25	Group effect		Controls vs CD-	Controls vs CD+	CD- vs CD+
					$F_{73,2}$	p-value	p-value	p-value	p-value
Amygdala	Left	1534.92 (262.37)	1458.84 ^a (203.48)	1445.20 (262.42)	0.15	0.86	-	-	-
	Right	1680.27 (307.48)	1514.16 ^a (194.77)	1555.36 (303.67)					
Caudate	Left	3616.38 (445.57)	3401.85 (470.74)	3762.84 (527.12)	3.14	0.049*	0.37	0.069	0.019*
	Right	3575.08 (471.09)	3299.25 (543.56)	3716.60 (562.57)					
Hippocampus	Left	2536.00 (352.54)	2439.70 (310.38)	2313.60 (307.93)	11.05	<0.001***	0.082	<0.001***	0.020*
	Right	2851.97 (353.11)	2591.60 (350.44)	2469.96 (341.21)					
NAc	Left	463.57 (109.13)	481.05 (144.61)	480.88 (118.33)	0.83	0.44	-	-	-
	Right	552.27 (83.45)	535.40 (94.93)	578.12 (97.99)					
Pallidum	Left	1808.73 (260.72)	1714.75 (273.61)	1762.08 (204.90)	0.20	0.82	-	-	-
	Right	1644.95 (241.26)	1615.65 (251.78)	1657.20 (232.43)					
Putamen	Left	5675.56 ^b (737.79)	5456.35 (571.74)	5746.67 ^c (609.06)	0.20	0.82	-	-	-
	Right	5329.25 ^b (598.12)	5152.70 (458.69)	5390.67 ^c (655.83)					
Pituitary		571.35 (114.36)	530.75 (99.08)	603.28 (109.86)	2.77	0.069	-	-	-
Cerebellar GM	Left	61,121.89 (7066.92)	58,752.20 (5410.78)	59,729.70 (6808.16)	1.78	0.18	-	-	-
	Right	62,132.52 (7273.77)	61,676.75 (7400.55)	61,003.84 (5489.82)					
Cerebellar WM	Left	17,491.51 (2944.87)	17,050.75 (2796.21)	16,218.24 (2462.17)	4.50	0.014*	0.49	0.004**	0.063
	Right	17,642.70 (2567.07)	15,929.76 (2420.97)	16,533.40 (2333.73)					

NAc: nucleus accumbens; GM: grey matter; WM: white matter.

^a(n = 19); ^b(n = 36); ^c(n = 24).


*p < 0.05; **p < 0.01; ***p < 0.001.

models of maladaptive reward-learning and behaviour (Volkow et al., 2013). Our finding suggests that CD severity affects caudate volume, as recently reported (Chye et al., 2017), and adds to a body of inconclusive work on drug-related alteration in this area. Caudate volumes were not significantly different in a recent meta-analysis that compared brain volumes in regular cannabis users and controls

(Lorenzetti et al., 2019). The volume of the caudate may be affected in dependent users specifically (i.e. not in recreational non-problem users), and this alteration may be conflated because the cannabis using samples examined to date included both people with and without CD.

The impact of CD on neuroanatomy may be regionally specific and driven by distinct mechanisms. Effect sizes

Figure 1. Significance map of shape analysis showing comparison in right and left hippocampus (superior and inferior view) between healthy controls (HC) versus low-dependence cannabis users (CD-), HC versus high-dependence cannabis users (CD+) and CD- versus CD+, including raw and false discovery rate (FDR)-corrected group differences, and their visual representation using heat maps plotted into deformable models of hippocampal surface (signed difference).



and FDR correction showed that group differences in caudate volumes were less marked than those in the hippocampus and cerebellum. The hippocampus and cerebellum have a higher concentration of cannabinoid receptors than the caudate (Glass et al., 1997) and may be more vulnerable to the effects of tetrahydrocannabinol (THC), the key cannabinoid compound which determines cannabis potency and addiction liability. In contrast, alterations of the caudate may reflect a neuroadaptation resulting from habitual substance use (Schwabe and Wolf, 2011) as observed in samples dependent on substances other than cannabis, such as cocaine (Pierce and Vanderschuren, 2010), alcohol (Sjoerds et al., 2013) and gaming (Ko et al., 2009).

The CD-specific effects that we report here add to emerging evidence that dependence drives brain structural and functional differences in regular cannabis users (Chye et al., 2017; Filbey and Dunlop, 2014). Previous work has emphasised a lack of dose-dependent relationships in brain areas that differ between cannabis users and non-users,

pointing towards a need to carefully re-evaluate the role of dosage versus dependence in the neuroalterations reported in cannabis users. Alteration of striatal dopaminergic pathways (Bloomfield et al. 2016; van de Giessen et al. 2017), which have been associated with dependence severity (Volkow et al., 2013), may underlie the neuroanatomical differences between cannabis users and controls (Woodward et al. 2009). However, to our knowledge, no study has specifically examined the association between CD, dopaminergic function and striatal (including caudate) volume.

Our sample did not show volumetric alterations of several brain regions (e.g. amygdala, ventral striatum) implicated in neuroscientific theories of addiction (Casajuana et al., 2016; Everitt and Robbins, 2016; Koob, 2009; Volkow et al., 2013). As these theories rely mostly on pre-clinical studies of substance use and on drugs other than cannabis (e.g. alcohol), our results suggest that exposure to cannabis versus other substances implicates partially distinct neural pathways. This notion needs validation in larger

samples and systematic comparison between users of cannabis and other substances.

Our findings warrant examination of CD – rather than dosage/frequency/age of onset alone – in future studies of cannabis users. The previously reported hippocampal and cerebellar volume alterations in samples of recreational/regular cannabis users (not segregated by dependence level) may be driven by a subgroup of more severely dependent users. Notably, CD+ in this study smoked cannabis more frequently (5 days/month on average or more) than CD–, but otherwise the groups did not differ on duration of cannabis use or cumulative lifetime dosage (see Table 1). Lifetime dosage encapsulated frequency of use (calculated as cannabis quantity used/month \times number of smoking days/month \times years of use), and yet was not a significant predictor of brain volumes in regression analyses.

This study is limited by the lack of a rigorous diagnostic assessment of cannabis use disorder (CUD; *Diagnostic and Statistical Manual of Mental Disorders* [5th ed.; DSM-5]; APA, 2013). Replication is warranted in larger samples with varying levels of CUD severity (i.e. mild, moderate and severe) and sensitive measures of cannabis dosage, frequency, duration, onset and dependence. Another limitation is that our exploratory shape analyses were not performed for brain regions other than the hippocampus (e.g. cerebellum, caudate). The hippocampus is most often implicated in cannabis use-related neuroalterations (both volume and shape), where studies have shown consistently stronger effect size in comparison with other structures (Lorenzetti et al., 2019). As such, the shape analysis in this paper allowed us to extend hippocampal findings to understand surface-related differences associated with CD. Finally, we did not assess the neural effects of distinct cannabinoid compounds with neuroprotective and neurotoxic properties (e.g. THC and cannabidiol), motivation for using cannabis and self-medication, and perceived beneficial effects from using. These factors are largely unexplored and should be assessed in future work to inform a detailed understanding of the neural correlates of cannabis use and policies on the decriminalisation of cannabis products.

Our findings indicate that CD is related to volumetric alterations in specific brain regions, including the hippocampus and the cerebellum (where group differences had the strongest effect sizes) and the caudate. This work complements emerging structural neuroimaging findings showing that the structure of other cortical brain regions (i.e. orbitofrontal cortex) is associated with CD, rather than recreational non-dependent use (Chye et al., 2017). Future work will be necessary to verify whether alterations in reward, stress and addiction-relevant brain circuits are associated more with dependence on cannabis (i.e. dependence-related effects) than regular non-problem cannabis use per se (e.g. effects due to exposure to cannabinoids),

and how CD-related alterations may differ from those of dependence on other drugs.

Acknowledgements

This research was conducted at the Children's MRI Centre, Royal Children's Hospital, Melbourne Victoria. It was supported by the Murdoch Children's Research Institute and Royal Children's Hospital.



Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Funding

The author(s) received the following financial support for the research, authorship and/or publication of this article: This study was supported by a NHMRC Project Grant (#459111). Yann Chye was supported by a Monash Postdoctoral Bridging Fellowship. Sarah Whittle was supported by a National Health and Medical Research Council (NHMRC) Career Development Fellowship L2 (APP1125504). Christos Pantelis was supported by a NHMRC Senior Principal Research Fellowship (1105825). Alex Fornito was supported by the Sylvia and Charles Viertel Foundation.

ORCID iDs

Valentina Lorenzetti  <https://orcid.org/0000-0002-5917-7068>
Dan I Lubman  <https://orcid.org/0000-0002-6747-1937>

References

- American Psychiatric Association (APA) (2013) *DSM-V Diagnostic and Statistical Manual of Mental Disorders*, 4th Edition. Washington, DC: APA.
- Bliethikioti C, Miquel L, Batalla A, et al. (2019) Cerebellar alterations in cannabis users: A systematic review. *Addiction Biology*. Epub ahead of print 27 February. DOI: 10.1111/adb.12714.
- Bloomfield MA, Ashok AH, Volkow ND, et al. (2016) The effects of Δ 9-tetrahydrocannabinol on the dopamine system. *Nature* 539: 369–377.
- Bodlund O, Kullgren G, Ekselius L, et al. (1994) Axis V – Global assessment of functioning scale. Evaluation of a self-report version. *Acta Psychiatrica Scandinavica* 90: 342–347.
- Budney AJ, Novy PL and Hughes JR (1999) Marijuana withdrawal among adults seeking treatment for marijuana dependence. *Addiction* 94: 1311–1322.
- Budney AJ, Sofis MJ and Borodovsky JT (2019) An update on cannabis use disorder with comment on the impact of policy related to therapeutic and recreational cannabis use. *European Archives of Psychiatry and Clinical Neuroscience* 269: 73–86.
- Casajuana C, López-Pelayo H, Balcels MM, et al. (2016) Definitions of risky and problematic cannabis use: A systematic review. *Substance Use & Misuse* 51: 1760–1770.
- Chye Y, Solowij N, Suo C, et al. (2017) Orbitofrontal and caudate volumes in cannabis users: A multi-site mega-analysis comparing dependent versus non-dependent users. *Psychopharmacology* 234: 1985–1995.
- Chye YY, Lorenzetti V, Suo C, et al. (2019) Alteration to hippocampal volume and shape confined to cannabis dependence: A multisite study. *Addiction Biology* 24: 822–834.
- Convit A, McHugh P, Wolf OT, et al. (1999) MRI volume of the amygdala: A reliable method allowing separation from the hippocampal formation. *Psychiatry Research: Neuroimaging* 90: 113–123.

- Cook M, Fish D, Shorvon S, et al. (1992) Hippocampal volumetric and morphometric studies in frontal and temporal lobe epilepsy. *Brain* 115: 1001–1015.
- Everitt BJ and Robbins TW (2016) Drug addiction: Updating actions to habits to compulsions ten years on. *Annual Review of Psychology* 67: 23–50.
- Filbey FM and Dunlop J (2014) Differential reward network functional connectivity in cannabis dependent and non-dependent users. *Drug and Alcohol Dependence* 140: 101–111.
- Garner B, Pariante CM, Wood SJ, et al. (2005) Pituitary volume predicts future transition to psychosis in individuals at ultra-high risk of developing psychosis. *Biological Psychiatry* 58: 417–423.
- Glass M, Faull RLM and Dragunow M (1997) Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. *Neuroscience* 77: 299–318.
- Gossop M, Darke S, Griffiths P, et al. (1995) The Severity of Dependence Scale (SDS): Psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. *Addiction* 90: 607–614.
- Ko C-H, Liu G-C, Hsiao S, et al. (2009) Brain activities associated with gaming urge of online gaming addiction. *Journal of Psychiatric Research* 43: 739–747.
- Konings M, Bak M, Hanssen M, et al. (2006) Validity and reliability of the CAPE: A self-report instrument for the measurement of psychotic experiences in the general population. *Acta Psychiatrica Scandinavica* 114: 55–61.
- Koob GF (2009) Neurobiological substrates for the dark side of compulsivity in addiction. *Neuropharmacology* 56: 18–31.
- Lorenzetti V, Chye Y, Silva P, et al. (2019) Does regular cannabis use affect neuroanatomy? An updated systematic review and meta-analysis of structural neuroimaging studies. *European Archives of Psychiatry and Clinical Neuroscience* 269: 59–71.
- Lorenzetti V, Solowij N and Yücel M (2016) The role of cannabinoids in neuroanatomic alterations in cannabis users. *Biological Psychiatry* 79: e17–e31.
- Lorenzetti V, Solowij N, Whittle S, et al. (2015) Gross morphological brain changes with chronic, heavy cannabis use. *The British Journal of Psychiatry* 206: 77–78.
- MacMaster FP and Kusumakar V (2004) MRI study of the pituitary gland in adolescent depression. *Journal of Psychiatric Research* 38: 231–236.
- MacMaster FP, Russell A, Mirza Y, et al. (2006) Pituitary volume in treatment-naïve pediatric major depressive disorder. *Biological Psychiatry* 60: 862–866.
- Pariante CM, Vassilopoulou K, Velakoulis D, et al. (2004) Pituitary volume in psychosis. *The British Journal of Psychiatry* 185: 5–10.
- Pierce RC and Vanderschuren LJ (2010) Kicking the habit: The neural basis of ingrained behaviors in cocaine addiction. *Neuroscience and Biobehavioral Reviews* 35: 212–219.
- Pol P, Liebrechts N, Graaf R, et al. (2013) Mental health differences between frequent cannabis users with and without dependence and the general population. *Addiction* 108: 1459–1469.
- Sassi RB, Nicoletti M, Brambilla P, et al. (2001) Decreased pituitary volume in patients with bipolar disorder. *Biological Psychiatry* 50: 271–280.
- Schwabe L and Wolf OT (2011) Stress-induced modulation of instrumental behavior: From goal-directed to habitual control of action. *Behavioural Brain Research* 219: 321–328.
- Sjoerds Z, de Wit S, van den Brink W, et al. (2013) Behavioral and neuroimaging evidence for overreliance on habit learning in alcohol-dependent patients. *Translational Psychiatry* 3: e337.
- Sobell LC and Sobell MB (1992) *Timeline Follow-back: A Technique for Assessing Self-reported Alcohol Consumption*. Totowa, NJ: Humana Press.
- Solowij N, Jones KA, Rozman ME, et al. (2011a) Verbal learning and memory in adolescent cannabis users, alcohol users and non-users. *Psychopharmacology* 216: 131–144.
- Solowij N, Stephens RS, Roffman RA, et al. (2002) Cognitive functioning of long-term heavy cannabis users seeking treatment. *JAMA* 287: 1123–1131.
- Solowij N, Walterfang M, Lubman DI, et al. (2013) Alteration to hippocampal shape in cannabis users with and without schizophrenia. *Schizophrenia Research* 143: 179–184.
- Solowij N, Yücel M, Respondek C, et al. (2011b) Cerebellar white-matter changes in cannabis users with and without schizophrenia. *Psychological Medicine* 41: 2349–2359.
- Spielberger CD (2010) *State-Trait Anxiety Inventory*. Hoboken, NJ: John Wiley & Sons.
- Takagi M, Lubman DI, Cotton S, et al. (2011a) Executive control among adolescent inhalant and cannabis users. *Drug and Alcohol Review* 30: 629–637.
- Takagi M, Yücel M, Cotton SM, et al. (2011b) Verbal memory, learning, and executive functioning among adolescent inhalant and cannabis users. *Journal of Studies on Alcohol and Drugs* 72: 96–105.
- United Nations Office on Drugs and Crime (UNODC) (2016) World drug report 2016. In: UNDOC (ed.) *World Drug Report Series*. Vienna: UNDOC.
- van de Giessen E, Weinstein JJ, Cassidy CM, et al. (2017) Deficits in striatal dopamine release in cannabis dependence. *Molecular Psychiatry* 22: 68–75.
- Velakoulis D, Pantelis C, McGorry PD, et al. (1999) Hippocampal volume in first-episode psychoses and chronic schizophrenia: A high-resolution magnetic resonance imaging study. *Archives of General Psychiatry* 56: 133–141.
- Velakoulis D, Wood SJ, Wong MT, et al. (2006) Hippocampal and amygdala volumes according to psychosis stage and diagnosis: A magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. *Archives of General Psychiatry* 63: 139–149.
- Volkow ND, Wang G-J, Tomasi D, et al. (2013) Unbalanced neuronal circuits in addiction. *Current Opinion in Neurobiology* 23: 639–648.
- Watson C, Andermann F, Gloor P, et al. (1992) Anatomic basis of amygdaloid and hippocampal volume measurement by magnetic resonance imaging. *Neurology* 42: 1743–1743.
- Wechsler D (1999) *Manual for the Wechsler Abbreviated Scale of Intelligence*. San Antonio, TX: The Psychological Corporation.
- Woodward ND, Zald DH, Ding Z, et al. (2009) Cerebral morphology and dopamine D2/D3 receptor distribution in humans: a combined [18F] fallypride and voxel-based morphometry study. *Neuroimage* 46: 31–38.
- Yücel M, Solowij N, Respondek C, et al. (2008) Regional brain abnormalities associated with heavy long-term cannabis use. *Archives of General Psychiatry* 65: 1–8.